EGFR and lung carcinoma: Next, to evaluate the predictive value of the supercluster signatures for therapy response, we analyzed a dataset comprising pre-treatment tumor samples from eight patients with EGFR-mutant lung cancer treated with the tyrosine kinase inhibitor Osimertinib[38].